Romero et al. conducted a CRISPR/Cas9 genetic screen with KEAP1-mutant lung cancer cells and found that NRF2-addicted cancer cells are highly dependent on glutamine uptake, and that, consequently, inhibition of glutamine-derived glutamate by glutaminase inhibition effectively suppresses NRF2-addicted lung cancers (Romero et al. 2017; Mukhopadhyay et al. 2020). The gene discussed is KEAP1; the disease is lung carcinoma.